Mesoblast Financial Ratios
NASDAQ: MESOHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Mesoblast ratio analysis
Mesoblast earned a net margin of -593.9% in FY 2025, up from -1490.3% a year earlier. Gross margin was 70.2% compared with a median of 100.0% over the prior 2 years. Return on equity reached -17.1%, meaning Mesoblast generated -0.17 dollars of profit for every dollar of shareholders' equity.
Debt-to-equity stood at 0.29 versus 0.27 the year before, and the current ratio was 1.99. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Mesoblast financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Price / sales | 750.04 | 1,138.50 | 810.79 | 327.69 | 1,271.33 | 396.01 | 313.98 | 295.40 | 2,630.50 | 73.62 |
| Price / book | 21.59 | 13.99 | 12.12 | 6.73 | 16.26 | 23.18 | 10.91 | 9.38 | 12.28 | 5.93 |
| Gross margin | 70.2% | 100.0% | 100.0% | — | — | — | — | — | — | — |
| Net margin | -593.9% | -1,490.3% | -1,091.7% | -894.6% | -1,329.2% | -242.4% | -537.0% | -203.5% | -3,184.7% | -9.7% |
| Free cash flow margin | -294.4% | -825.6% | -847.0% | -644.2% | -1,355.2% | -156.8% | -345.6% | -432.6% | -3,958.2% | -206.8% |
| Return on equity (ROE) | -17.1% | -18.3% | -16.3% | -18.4% | -17.0% | -14.2% | -18.7% | -6.5% | -14.9% | -0.8% |
| Return on assets (ROA) | -13.0% | -13.1% | -12.2% | -13.8% | -13.3% | -10.6% | -13.8% | -5.1% | -11.7% | — |
| Debt / equity | 0.29 | 0.27 | 0.23 | 0.20 | 0.25 | 0.22 | 0.20 | 0.11 | — | — |
| Current ratio | 1.99 | 1.18 | 1.95 | 1.36 | 1.57 | 1.51 | 1.41 | 4.21 | 1.73 | — |
| Revenue growth | 191.4% | -21.3% | -26.5% | 37.4% | -76.9% | 92.3% | -3.6% | 618.9% | -94.3% | — |